A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers

PURPOSE: Stimulation of effector T cells is an appealing immunotherapeutic approach in oncology. OX40 (CD134) is a costimulatory receptor expressed on activated CD4(+) and CD8(+) T cells. Induction of OX40 following antigen recognition results in enhanced T-cell activation, proliferation, and surviv...

Descripción completa

Detalles Bibliográficos
Autores principales: Diab, Adi, Hamid, Omid, Thompson, John A., Ros, Willeke, Eskens, Ferry A.L.M., Doi, Toshihiko, Hu-Lieskovan, Siwen, Klempner, Samuel J., Ganguly, Bishu, Fleener, Catherine, Wang, Xiao, Joh, Tenshang, Liao, Ken, Salek-Ardakani, Shahram, Taylor, Carrie Turich, Chou, Jeffrey, El-Khoueiry, Anthony B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401502/
https://www.ncbi.nlm.nih.gov/pubmed/34615725
http://dx.doi.org/10.1158/1078-0432.CCR-21-0845

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401502/
https://www.ncbi.nlm.nih.gov/pubmed/34615725
http://dx.doi.org/10.1158/1078-0432.CCR-21-0845

Ejemplares similares